Uniqure NV (QURE) Stock Analysis

Uniqure NV (QURE) is a publicly traded company in the HEALTHCARE sector. It trades at $26.76, carries a market capitalization of $1.78B. This page summarizes the public market data, fundamentals, and frequently asked questions for QURE, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $26.76
• Market Cap: $1.78B
• EPS: $-3.49
• 52-Week High: $71.50
• 52-Week Low: $8.73

Market Sentiment

Uniqure NV currently has a Neutral sentiment score of 0.09.

About Uniqure NV

uniQure NV is a pioneering gene therapy company focused on developing innovative treatments for patients with genetic disorders and other severe diseases. Headquartered in Amsterdam, the Netherlands, uniQure leverages its proprietary AAV-based gene therapy platform to address unmet medical needs, aiming to provide long-lasting solutions for conditions such as hemophilia and neurodegenerative diseases. With a robust pipeline of product candidates and a commitment to transforming patient care t...

GNG Research Analysis

GNG Research scores Uniqure NV (QURE) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for QURE.

Frequently Asked Questions

Does QURE pay dividends?

Uniqure NV (QURE) does not currently pay a regular dividend.

What is QURE's market cap?

Uniqure NV (QURE) has a market capitalization of $1.78B with a current stock price of $26.76.